|
 |
Volume 1, Number 4 (November/December 2004) | |||||
Letter from the Editor |
|||||
201 |
Weathering the Medicare storm The West Clinic, Memphis, TN Change is afoot in medical oncology. We are just weeks away from the enactment of the Medicare Modernization Act of 2003, which thrusts an untested method of drug reimbursement into a cancer care delivery system already struggling to absorb profound changes coming from many directions. What can practices, whether large or small, do to deal with the uncertainty? Community Oncology’s Editor-in-Chief offers concrete suggestions.
|
||||
Community Translations |
|||||
205 |
Bevacizumab in metastatic colorectal cancer and other settings A landmark study in the treatment of colon cancer is the first to document the clinical benefit of antiangiogenic therapy. Bevacizumab has also shown promising activity in studies of non-small cell lung cancer and renal cell carcinoma, but the benefits and toxicities need to be explored further.
|
||||
208 |
Platinum-based adjuvant therapy improves outcome in early NSCLC The most important presentations at the American Society of Clinical Oncology’s 2004 annual meeting were the two adjuvant therapy studies in completely resected patients with stage IB and II non-small cell lung cancer. Both showed clinically important and highly statistically significant improvements in survival with adjuvant chemotherapy.
|
||||
Original Research |
|||||
211 |
The impact of medical visits for chemotherapy-induced anemia and neutropenia on the patient and caregiver: a national survey Accelerated Community Oncology Research Network and The West Clinic, Memphis, TN They must make many clinic visits for treatment and supportive care. How do these repeated trips to the doctor—especially for anemia and neutropenia—affect patients and caregivers? And are all the visits really necessary? The authors conducted a national survey to find out.
|
||||
Controversies in Patient Management |
|||||
219 |
Aromatase inhibitors in adjuvant therapy: promise and uncertainty University of Texas Health Sciences Center, San Antonio, TX The advent of aromatase inhibitors marks a broadening and an improvement in the options available for the adjuvant therapy of patients with hormone-responsive breast cancer. But there’s also more uncertainty, particularly beyond the first 5 years of treatment. Questions remain about long-term safety and the best strategy for using these agents.
|
||||
Economics/Practice Management |
|||||
226 |
The smart medical oncology partnership Matrix Oncology, Fort Worth, TX Choose your partner carefully, create a non-competitive environment, empower and value good management. As a recipe for world peace, it’s a work in progress. But you can apply these principles now for a harmonious partnership.
|
||||
Challenging Cases/Rare Cancers |
|||||
232 |
von Hippel-Lindau syndrome Medical Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD A comprehensive review of a multisystem, neoplastic heritable disorder of high penetrance in affected individuals who carry the autosomal dominantly inherited trait. This review includes a resource list of experts on whom readers can call when confronted with this challenging disorder.
|
||||
Letters to the Editor |
|||||
204 |
Easing the tension between oncologists and hospice
|
||||
204 |
Wider access to clinical trials
|
||||
Washington Update |
|||||
245 |
Medicare tries to get it right
| ||||
245 |
Reporting on quality-of-life indicators—and getting paid for it
| ||||
246 |
Grassroots outreach making headway
| ||||
250 |
Quality measures for oncology coalescing
|
||||
Reader Services |
|||||
251 |
Guide for Authors
| ||||
252 |
2004 Annual Index
| ||||
© 2004 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
|||||
63 kb